D. Najarian

发表

Olanzapine increases weight and serum triglyceride levels.

R. Dufresne, D. Osser, D. Najarian, 1999, The Journal of clinical psychiatry.

Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections

S. Gopal, C. Benson, I. Turkoz, 2022, Neuropsychiatric Disease and Treatment.

Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics

C. Correll, D. Najarian, Stephen R Saklad, 2018, CNS Spectrums.

NDT_A_373725 1927..1937

S. Gopal, C. Benson, I. Turkoz, 2022 .

Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations

E. Voss, D. Fife, S. Fortin, 2022, Neuropsychopharmacology reports.

Community pharmacists and mental illness: a survey of service provision, stigma, attitudes and beliefs

V. Giannetti, C. Caley, D. Najarian, 2018, International Journal of Clinical Pharmacy.

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia

S. Galderisi, S. Gopal, P. Lim, 2021, The international journal of neuropsychopharmacology.

An assessment of injection site reaction and injection site pain of 1‐month and 3‐month long‐acting injectable formulations of paliperidone palmitate

L. Alphs, M. Mathews, S. Gopal, 2018, Perspectives in psychiatric care.

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia

S. Gopal, U. Richarz, C. Benson, 2023, Neuropsychiatric disease and treatment.

P.0533 Paliperidone palmitate 6-month long-acting injectable for schizophrenia: A randomised, double-blind, multicenter, noninferiority phase 3 study

S. Galderisi, S. Gopal, P. Lim, 2021, European Neuropsychopharmacology.

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

M. Mathews, S. Gopal, A. Savitz, 2018, Neuropsychiatric disease and treatment.

Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

S. Galderisi, U. Richarz, I. Turkoz, 2023, The international journal of neuropsychopharmacology.

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

M. Mathews, S. Gopal, A. Savitz, 2018 .